{"disease":{"id":"recurrent-or-metastatic-solid-tumors","name":"recurrent or metastatic solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06330064","title":"A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06031441","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03330405","title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06093698","title":"An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"ITabMed Co., Ltd.","has_results":false},{"nct_id":"NCT07015697","title":"A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT02221960","title":"A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT07123493","title":"Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Haifeng Qin","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}